River Road Asset Management’s Myriad Genetics MYGN Stock Holding History

River Road Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-400,610	Closed	-$12.3M	–	157
2016 Q2	$12.3M	Buy	+400,610	New	+$13.9M	0.26%	102
2015 Q4	–	Sell	-494,890	Closed	-$18.5M	–	165
2015 Q3	$18.5M	Sell	494,890 -136,825	-22%	-$4.86M	0.29%	82
2015 Q2	$21.5M	Sell	631,715 -176,294	-22%	-$5.99M	0.32%	80
2015 Q1	$28.6M	Sell	808,009 -183,923	-19%	-$6.58M	0.39%	72
2014 Q4	$33.8M	Sell	991,932 -88,602	-8%	-$3.14M	0.48%	65
2014 Q3	$41.7M	Buy	1,080,534 +48,556	+5%	+$1.81M	0.58%	53
2014 Q2	$40.2M	Buy	1,031,978 +292,403	+40%	+$10.9M	0.53%	63
2014 Q1	$25.3M	Sell	739,575 -745,355	-50%	-$23.1M	0.27%	95
2013 Q4	$31.2M	Buy	+1,484,930	New	+$37.6M	0.34%	84

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

River Road Asset Management's MYGN Position: Q3 2016 in Review

River Road Asset Management sold out of Myriad Genetics (MYGN) in Q3 2016, closing a stake of 400,610 shares — an estimated $12.3M sold.

River Road Asset Management first reported a position in MYGN in Q4 2013 and held it in 9 quarters. The position peaked at $41.7M in Q3 2014. 223 funds tracked by Wall St. Rank hold MYGN as of Q3 2016.

River Road Asset Management reported no remaining Myriad Genetics position as of Q3 2016 after selling out during the quarter.
River Road Asset Management sold 400,610 Myriad Genetics shares in Q3 2016, an estimated $12.3M.
River Road Asset Management first reported a position in Myriad Genetics in Q4 2013 and held it in 9 quarters.
River Road Asset Management's Myriad Genetics position peaked at $41.7M in Q3 2014.
223 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2016.

Based on River Road Asset Management's 13F filing for Q3 2016, filed 27 Oct 2016.